Evotec SE has entered a strategic R&D collaboration with Odyssey Therapeutics to discover new treatments for autoimmune and inflammatory diseases. The partnership leverages Evotec's AI-driven discovery platform, advanced screening, and proprietary compound libraries combined with Odyssey's expertise in disease biology. This collaboration aims to accelerate the identification of promising drug candidates and speed up early-stage research to develop innovative therapies addressing high unmet medical needs. Financial details were not disclosed, but Evotec will receive milestone payments based on successful discovery outcomes.
Japanese software firm Micware, through its subsidiary Micware Navigations, has partnered with Wiz Ltd. to offer cloud and AI security solutions leveraging Wiz's platform. This initiative addresses growing security complexities in AI and cloud enviro...
Pandora announced that CFO Anders Boyer will retire on November 30, 2026, after over 14 years with the company. Paulo Garcia, with 25 years of international experience in consumer goods and former CFO of Walmart Mexico & Central America, will join Pa...
RENK Group AG reported a record order intake of around €1.2 billion in the first half of 2026, a 29.7% increase from the previous year, driven by strong demand in defense. Revenue rose slightly by 2.7% to €637.2 million, while adjusted EBIT grew by 1...
RENK Group AG reported a record €1.2 billion in orders for the first half of 2026, a 29.7% increase from the previous year, driven by strong demand in defense. The company achieved its highest-ever quarterly order intake of €612.8 million in Q2, with...
Mowi ASA will present its second quarter 2026 financial results on August 18, 2026, at 08:00 CET in Oslo, Norway. The presentation will be conducted in English and streamed live online, followed by a Q&A session allowing participants to submit questi...
